DAFTAR PUSTAKA

1. Statland J, Ciafaloni E. Myasthenia gravis: Five new things. Neurol Clin Pract. 2013;3(2):126-33.
2. Yi J, Guptill J, Stathopoulos P, Nowak R, O'Connor K. B cells in the pathophysiology of myasthenia gravis. Muscle Nerve. 2017;57(2):172-84.
3. Stojanov A, Milošević V, Đorđević G, Stojanov J. Quality of Life of Myasthenia Gravis Patients in Regard to Epidemiological and Clinical Characteristics of the Disease. Neurologist. 2019;24(4):115-20.
4. Meriggioli M, Sanders D. Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol. 2009;8(5):475-90.
5. Guptill J, Sanders D, Evoli A. Anti-musk antibody myasthenia gravis: Clinical findings and response to treatment in two large cohorts. Muscle Nerve. 2011;44(1):36-40.
6. Amandusson Å, Elf K, Grindlund M, Punga A. Diagnostic Utility of Repetitive Nerve Stimulation in a Large Cohort of Patients With Myasthenia Gravis. J Clin Neurophysiol. 2017 ;34(5):400-7.
7. Abraham A, Breiner A, Barnett C, Katzberg H, Lovblom L, RT M et al. Electrophysiological testing is correlated with myasthenia gravis severity. Muscle Nerve. 2017;56(3):445-8.
8. Liik M, Punga A. Repetitive nerve stimulation often fails to detect abnormal decrement in acute severe generalized Myasthenia Gravis. Clin Neurophysiol. 2016;127(11):3480-4.
9. Ropper A, Samuels M, Klein J. Adam and Victor's Principles of Neurology. 10th ed. New York: McGraw-Hill education; 2014.
10. Wang Z, Yan Y. Immunopathogenesis in Myasthenia Gravis and Neuromyelitis Optica. Front Immunol. 2017;8(1785):2-3.
11. Ohira M, Jeong D, Oh S. Seropositive Myasthenia Gravis Associated with Small-Cell Lung Carcinoma. J Clin Neurol. 2011;7(1):43.
12. Gilhus N, Owe J, Hoff J, Romi F, Skeie G, Aarli J. Myasthenia Gravis: A Review of Available Treatment Approaches. Autoimmune Dis. 2011;2011:847393.
13. Carr A, Cardwell C, McCarron P, McConville J. A systematic review of population based epidemiological studies in Myasthenia Gravis. BMC Neurol. 2010;10(1):46.
14. Jayam Trouth A, Dabi A, Solieman N, Kurukumbi M, Kalyanam J. Myasthenia Gravis: A Review. Autoimmune Dis. 2012;2012:874680.
15. Conti-Fine B, Milani M, Kaminski H. Myasthenia gravis: past, present, and future. J Clin Invest. 2006;116(11):2843-54.
16. Gilhus N, Tzartos S, Evoli A, Palace J, Burns T, Verschuuren J. Myasthenia gravis. Nat Rev Dis Primers. 2019;5(1):30.

17. Preston D, Shapiro B. Repetitive Nerve Stimulation. Electromyography and Neuromuscular Disorder. 3rd ed. London: Elsevier Saunders; 2013. p. 52-61.
18. Cherian A, Baheti N, Iype T. Electrophysiological study in neuromuscular junction disorders. Ann Indian Acad Neurol. 2013;16(1):34.
19. Phillips W, Vincent A. Pathogenesis of myasthenia gravis: update on disease types, models, and mechanisms. F1000Res. 2016;5:1513.
20. Jaretzki A, Barohn R, Ernstoff R, Kaminski H, Keesey J, Penn A et al. Myasthenia gravis: recommendations for clinical research standards. Neurology. 2000;55(1)16-23.
21. Howard J. Myasthenia gravis: A Manual for the Heath Care Provider. 1st ed. St. Paul: Myasthenia Gravis Foundation of America; 2008. p. 20-23.
22. Scherer K. Does This Patient Have Myasthenia Gravis?. JAMA. 2005;293(15):1906-14.
23. Pasnoor M, Dimachkie M, Farmakidis C, Barohn R. Diagnosis of Myasthenia Gravis. Neurol Clin. 2018;36(2):261-74.
24. AAEM Quality Assurance Committee. American Association of Electrodiagnostic Medicine. Practice parameter for repetitive nerve stimulation and single fiber EMG evaluation of adults with suspected myasthenia gravis or Lambert-Eaton myasthenic syndrome: summary statement. Muscle Nerve. 2001;24(9):1236-8.
25. Farmakidis C, Pasnoor M, Dimachkie M, Barohn R. Treatment of Myasthenia Gravis. Neurol Clin. 2018;36(2):311-37.
26. Sanders D, Wolfe G, Benatar M, Evoli A, Gilhus N, Illa I et al. International consensus guidance for management of myasthenia gravis. Neurology. 2016;87(4):419-25.
27. Burns T, Jones H. Myasthenia Gravis. In: Jones H, Srinivasan J, Allam G, Baker R, ed. by. Netter's Neurology. 2nd ed. Philapelphia: Elsevier Saunders; 2012. p. 689.
28. Barnett C, Herbelin L, Dimachkie M, Barohn R. Measuring Clinical Treatment Response in Myasthenia Gravis. Neurol Clin. 2018;36(2):339-53.
29. Sugiarto C, Sadeli H, Murni T. Perbandingan Dosis Piridostigmin, Performa Fungsional, dan Derajat Klinis Pasien Miastenia Gravis Sebelum dan Setelah Timektomi. Neurona. 2018;35(4):245-51.
30. Muppidi S, Wolfe G, Conaway M, Burns T. MG-ADL: Still a relevant outcome measure. Muscle Nerve. 2011;44(5):727-31.
31. Kamus Besar Bahasa Indonesia Daring. 2016. Jakarta: Departemen Pendidikan dan Kebudayaan RI.
32. Abraham A, Lovblom LE, Bril V. Baseline Decrement in Patients with Mild Myasthenia Gravis Predicts Immunomodulation Treatment. Can J Neurol Sci. 2019;46(6):762-6.
33. Zinman L, Baryshnik D, Bril V. Surrogate Therapeutic Outcome Measures in Patients with Myasthenia Gravis. Muscle Nerve. 2008;37(2):172-6.